


# WHO recommendation on **Prophylactic antibiotics** for women undergoing caesarean section





WHO recommendation on  
**Prophylactic antibiotics  
for women undergoing  
caesarean section**

WHO recommendation on prophylactic antibiotics for women undergoing caesarean section

ISBN 978-92-4-002801-2 (electronic version)

ISBN 978-92-4-002802-9 (print version)

© **World Health Organization 2021**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

**Suggested citation.** WHO recommendation on prophylactic antibiotics for women undergoing caesarean section. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Edited by Green Ink. Designed by minimum graphics.

# Contents

Acknowledgements	v
Acronyms and abbreviations	vi
Executive summary	vii
Introduction	vii
Target audience	vii
Guideline development methods	vii
Recommendation	viii
1. Introduction	1
1.1 Background	1
1.2 Rationale and objectives	2
1.3 Target audience	2
1.4 Scope of the recommendation	2
1.5 Persons affected by the recommendation	2
2. Methods	3
2.1 Contributors to the guideline	3
2.2 Identification of priority questions and outcomes	4
2.3 Evidence identification and retrieval	5
2.4 Certainty assessment and grading of the evidence	5
2.5 Formulation of the recommendation	6
2.6 Management of declarations of interests	8
2.7 Decision-making during the GDG meetings	8
2.8 Document preparation	9
2.9 Peer review	9
3. Guiding principles, best practice, recommendation and supporting evidence	10
3.1 Guiding principles and best practice	10
3.2 Recommendation and supporting evidence	11
4. Dissemination, adaptation and implementation of the recommendation	14
4.1 Recommendation dissemination	14
4.2 Adaptation	14
4.3 Implementation considerations	14
5. Research implications	15
6. Applicability issues	15
6.1 Anticipated impact on the organization of care and resources	15
6.2 Monitoring and evaluating guideline implementation	16
7. Updating the recommendation	16
8. References	17
Annex 1. External experts and WHO staff involved in the preparation of the recommendation	21
Annex 2. Priority outcomes used in decision-making	24
Annex 3. Summary and management of declared interests from GDG members	25
Annex 4. Evidence-to-decision framework	26



# Acknowledgements

The Department of Sexual and Reproductive Health and Research, the Department of Maternal, Newborn, Child and Adolescent Health and Ageing, and the Antimicrobial Resistance Division and Infection Prevention & Control Technical and Clinical Hub of the World Health Organization (WHO) gratefully acknowledge the contributions of many individuals and organizations to the updating of this recommendation. Work on this update was coordinated by Mercedes Bonet, Doris Chou, Tina Lavin, Olufemi Oladapo and Joshua Vogel of the Department of Sexual and Reproductive Health and Research.

WHO extends its sincere thanks to Fatima Adamu, Subha Sri Balakrishnan, Michelle Bazari, Maria Laura Costa, Jemima Dennis-Antiwi, Hadiza Galadanci, David Lissauer, Pisake Lumbiganon, Ashraf Nabhan, Hiromi Obara, Alfred Osofi, Haroon Saloojee, Sadia Shakoore, Rachel Smith and Joseph Solomkin who served as members of the Guideline Development Group (GDG), and to James Neilson (Chair) for leading the meeting. We also thank Ayse Akin, Justus Hofmeyr, Tina Lavender, Suneeta Mittal, Alan Tita, Khalid Yunis and John Varallo, who were members of the External Review Group (ERG). WHO also gratefully acknowledges the contribution of the members of the Executive Guideline Steering Group (GSG).

Edgardo Abalos, Anna Cuthbert, Virginia Diaz, Katherine Eddy, Leanne Jones, Frances Kellie, Myfanwy Williams and Rana Zahroh reviewed the scientific evidence, prepared the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tables and drafted the narrative summary of the evidence. Mercedes Bonet, Maurice Bucago, Doris Chou, Christine Francis, Tina Lavin, Olufemi Oladapo and Joshua Vogel revised the narrative summaries and double-checked the corresponding GRADE tables and prepared the evidence-to-decision (EtD) frameworks. The ERG peer reviewed the final document before executive clearance by WHO and publication.

We acknowledge the various organizations that were represented by observers, including Deborah Armbruster (United States Agency for International Development [USAID]), Emma Clark (USAID), Ann Yates (International Confederation of Midwives [ICM]), Jeanne Conry (International Federation of Gynecology and Obstetrics [FIGO]), Maria Fernanda Escobar (FIGO) and Jeff Smith (Bill & Melinda Gates Foundation).

We also appreciate the contributions of staff at the WHO regional offices, including Bremen de Mucio, Karima Gholbzouri, Chandani Anoma Jayathilaka, Oleg Kuzmenko, Leopold Ouedraogo, Howard Sobel and Claudio Sosa. We appreciate the contributions of Willibald Zeck of the United Nations Population Fund (UNFPA).

WHO acknowledges the financial support for this work received from USAID and the UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP) of the Department of Sexual and Reproductive Health and Research. WHO emphasizes that donors do not participate in any decision related to the guideline development process, including the composition of research questions, membership of the guideline development groups, conducting and interpretation of systematic reviews, or formulation of the recommendations. The views of the funding bodies have not influenced the content of this recommendation.

## Acronyms and abbreviations

CerQUAL	Confidence in the Evidence from Reviews of Qualitative Research
CHEC	Consensus Health Economic Criteria
DOI	declaration of interest
ERG	Evidence Review Group
ESG	Evidence Synthesis Group
EtD	evidence-to-decision
FIGO	International Federation of Gynecology and Obstetrics
GDG	Guideline Development Group
GRADE	Grading of Recommendations Assessment, Development and Evaluation
GSG	Guideline Steering Group
HRP	UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction
ICM	International Confederation of Midwives
IU	international units
IV	intravenous
MPH-GDG	Maternal and Perinatal Health Guideline Development Group
PICO	population (P), intervention (I), comparator (C), outcome (O)
UNDP	United Nations Development Programme
UNFPA	United Nations Population Fund
UNICEF	United Nations Children's Fund
USAID	United States Agency for International Development
WHO	World Health Organization

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_23789](https://www.yunbaogao.cn/report/index/report?reportId=5_23789)

